Abstracts

Outlined below are the guidelines that must be followed when submitting a late breaking abstract submission to APLAR 2023. 

• A late breaking abstract submission should contain new information and high-impact scientific research where results were not available at the time of the general abstract submission deadline
• The scientific program committee will review all submitted abstracts. Notification regarding abstract acceptance and scheduling will be sent to the submitting author
• A limited number of late breaking abstracts will be accepted for an oral presentation. Some abstracts may be offered a poster presentation instead
• If the abstract is selected for either a poster or an oral presentation, you will not be eligible for early bird registration rates and must pay standard/late fees for the APLAR 2023 Congress
• Late breaking abstracts must not be a revision of an abstract submitted prior to the original submission deadline
• Late breaking abstracts must not have been presented or accepted for presentation at any other scientific meeting or published in any other journal at the time of submission
• Late breaking science abstracts will not be published in the International Journal of Rheumatic Diseases (IJRD). They will be available online on the APLAR 2023 Congress website as a PDF after the congress
• All general abstract submission guidelines must be followed in addition to the above points

All abstract submissions must be received online through the abstract submission portal.

Outlined below are the guidelines that must be followed when submitting your work to APLAR 2023. 

• All submissions must be in English. English is the official congress language and all presentations must also be in English
• Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
• Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
• Only standard abbreviations may be used within submissions
• References are not required for submissions
• The abstract title, section headings and references are not included in the overall word count
• Abstracts should follow the following format
  • Background/Purpose: background or statement of purpose
  • Methods: methods, materials and analytical procedure used
  • Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
  • Conclusion: conclusions reached
  • Tables, graphs and images are permitted within submissions (maximum 2)
• What is an encore presentation?
  An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event.
• Does APLAR 2022 accept encore presentations?
  • Yes we do accept encore presentations
  • Encore presentations are permitted as long as work has been presented after APLAR 2022 (6 – 9 December 2022)
  • Encore presentations are permitted as long as work has not previously been published prior to submission
  • Encore submissions are required to disclose the name and date of the event where it has been presented
• Original abstracts are strongly recommended

IMPORTANT
Please enter submission information carefully, information will be published exactly as submitted

All abstract submissions must be received online through the abstract submission portal.

• Advances in pain management
• Alternative medicine e.g. acupuncture
• Antiphospholipid syndrome
• Autoinflammatory diseases
• Basic science related to rheumatic diseases
• Behcet’s disease and miscellaneous rheumatic conditions
• Case report
• Clinical immunology related to rheumatic diseases
• COVID-19
• Crystal-induced diseases pathogenesis and risk factors
• Crystal-induced diseases clinical manifestations, outcomes, quality of life
• Crystal-induced diseases treatments
• Epidemiology, COPCORD, health care system and pharmacoeconomics
• Fibromyalgia
• Genetics
• Imaging techniques and diagnosis
• Infection-related rheumatic diseases
• Innovation in research tools i.e. big data, precision medicine
• Innovative medical technology i.e. Artificial Intelligence / machine learning
• Metabolic bone diseases
• Myositis and inflammatory myopathy pathogenesis and risk factors
• Myositis and inflammatory myopathy clinical manifestations, outcomes, quality of life
• Myositis and inflammatory myopathy treatments
• Osteoarthritis pathogenesis and risk factors
• Osteoarthritis clinical manifestations, outcomes, quality of life
• Osteoarthritis treatments
• Osteoporosis pathogenesis and risk factors
• Osteoporosis clinical manifestations, outcomes, quality of life
• Osteoporosis treatments
• Paediatric rheumatology
• Physiotherapy
• Psoriatic arthritis pathogenesis and risk factors
• Psoriatic arthritis clinical manifestations, outcomes, quality of life
• Psoriatic arthritis treatments
• Psychological intervention and miscellaneous forms of care
• Rehabilitation for rheumatic diseases
• Rheumatoid arthritis pathogenesis and risk factors
• Rheumatoid arthritis clinical manifestations, outcomes, quality of life
• Rheumatoid arthritis conventional DMARDs
• Rheumatoid arthritis biologic DMARDs and advance treatment
• Scleroderma and related disorders pathogenesis and risk factors
• Scleroderma and related disorders clinical manifestations, outcomes, quality of life
• Scleroderma and related disorders treatments
• Sjogren syndrome
• Soft tissue rheumatism
• Spondylarthropathies pathogenesis and risk factors
• Spondylarthropathies clinical manifestations, outcomes, quality of life
• Spondyloarthropathies conventional DMARDs
• Spondyloarthropathies biologic DMARDs and advance treatments
• Systemic lupus erythematosus pathogenesis and risk factors
• Systemic lupus erythematosus clinical manifestations, outcomes, quality of life
• Systemic lupus erythematosus treatments
• Systemic vasculitis pathogenesis and risk factors
• Systemic vasculitis clinical manifestations, outcomes, quality of life
• Systemic vasculitis treatments
• Telemedicine